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Abstract
Background: Stroke has been associated with rheumatoid arthritis (RA). We assessed patients with RA and healthy
control subjects by transcranial Doppler (TCD), carotid ultrasonography and brain magnetic resonance imaging (MRI).
Methods: Altogether, 41 female patients with RA undergoing methotrexate (MTX) or biologic treatment and 60
age-matched control subjects underwent TCD assessment of the middle cerebral artery (MCA) and basilar artery.
Pulsatility index (PI), resistivity (resistance) index (RI) and circulatory reserve capacity (CRC) were determined at rest (r)
and after apnoea (a) and hyperventilation (h). The presence of carotid plaques and carotid intima-media thickness
(cIMT) were also determined. Intracerebral vascular lesions were investigated by brain MRI.
Results: MCA PI and RI values at rest and after apnoea were significantly increased in the total and MTX-treated RA
populations vs control subjects. MCA CRC was also impaired, and basilar artery PI was higher in RA. More patients
with RA had carotid plaques and increased cIMT. Linear regression analysis revealed that left PI(r) and RI(r) correlated
with disease duration and that left PI(r), RI(r), PI(a), PI(h) and basilar PI correlated with disease activity. Right CRC
inversely correlated with 28-joint Disease Activity Score. Disease activity was an independent determinant of left PI(a)
and right CRC. Compared with long-term MTX treatment alone, the use of biologics in combination with MTX was
associated with less impaired cerebral circulation. Impaired cerebral circulation was also associated with measures of
carotid atherosclerosis.
Conclusions: To our knowledge, this is the first study to show increased distal MCA and basilar artery occlusion in RA
as determined by TCD. Patients with RA also had CRC defects. We also confirmed increased carotid plaque formation
and increased cIMT. Biologics may beneficially influence some parameters in the intracranial vessels.
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Background
Rheumatoid arthritis (RA) is a chronic inflammatory
rheumatic disease often involving the vascular and
nervous systems [1]. Accelerated atherosclerosis and
increased stroke morbidity and mortality have been
associated with RA [2–5]. According to a recent meta-
analysis, there is an excess risk of stroke (ORs ranging
from 1.51 to 2.13) [5]. Yet, to date, no systematic evalu-
ation of intracranial circulation has been performed.
Transcranial Doppler (TCD), first described in 1982, is
a non-invasive ultrasound (US) technique used to meas-
ure cerebral blood flow velocity in the major intracranial
arteries. It involves use of low-frequency (<2 MHz) US
waves to assess cerebral arteries through relatively thin
bone windows. TCD allows dynamic monitoring of cere-
bral circulation with a high temporal resolution. It is
relatively inexpensive, reproducible and portable [6, 7].
TCD may provide important information about the
pathophysiology and prognosis of cerebrovascular ische-
mia [7]. When assessing the middle cerebral artery
(MCA) by TCD, mean flow velocity (MFV), pulsatility
index (PI) and the PI/MFV ratio are prognostic factors
for recurrent vascular events [8]. Furthermore, asymp-
tomatic MCA stenosis, which can be detected by TCD,
may be an important risk for stroke [9].
One limitation of TCD is that approximately 8–20% of
individuals have inadequate temporal acoustic windows
(TAWs) [10]. There is an increased prevalence of TAW
failure in females and in elderly people [10]. Very re-
cently, we assessed TAW failure in patients with RA
compared with control subjects and found that TAW
failure was significantly more common among patients
with RA (Z. Kardos, C. Oláh, M. Sepsi, A. Sas, L.
Kostyál, T. Bóta, H. Bhattoa, K. Hodosi, G. Kerekes, L.
Tamási, D. Bereczki, Z. Szekanecz, unpublished data,
September 2017).
As described above, patients with RA are at very high
risk for cardiovascular and cerebrovascular disease. Nu-
merous studies have been performed on cardiovascular
disease and its surrogate markers. However, because
stroke is the second most common vascular complica-
tion in RA, there is a great need to assess cerebro-
vascular risk as well. Because very little information is
available with respect to intracranial vessels in RA, we
sought to assess the following: (1) to determine circula-
tion in the MCA, as well as in basilar arteries, by TCD
to determine whether there are abnormalities in intra-
cranial circulation in RA; (2) to assess the effects of anti-
tumour necrosis factor α biologics vs methotrexate
(MTX) treatment on TCD parameters; and (3) to correl-
ate intracranial circulation with carotid atherosclerosis
and brain vascular lesions. Therefore, we performed an
extensive study using TCD in patients with RA under-
going MTX or biologic treatment and compared them
with healthy control subjects. The functional TCD as-
sessment included the determination of several func-
tional parameters described later. We also assessed
carotid atherosclerosis by US and performed brain mag-
netic resonance imaging (MRI) to visualise vascular le-
sions as well as signs of emollition and atrophy. To our
knowledge, this is the first study to assess intracranial
vessels in patients with RA by TCD in conjunction with
carotid and brain examinations.
Methods
Patients and control subjects
Altogether, 41 patients with RA undergoing regular
follow-up at the Semmelweis Teaching Hospital,
Miskolc, Hungary, were recruited for the study. All these
patients had accessible TAWs as determined before the
TCD investigations. None of the patients with RA and
control subjects had any previous vascular events. The
major characteristics of these 41 patients are shown in
Table 1. All patients were female, and their mean age was
58.2 ± 9.7 years. Their mean disease duration was 12.2 ±
8.0 years. Altogether, 70% were immunoglobulin M (IgM)
rheumatoid factor (RF)-positive, and 65% were anti-cyclic
citrullinated peptide 2 antibody (anti-CCP2)-positive.
Among these patients, 12 were biologic-free. They had
been receiving MTX for a mean of 6.2 ± 5.8 years in an
average dose of 14.6 ± 6.1 mg/week. Altogether, 29 patients
had been receiving biologics (15 infliximab [IFX] and 14
tocilizumab [TCZ]) as first-line biologic treatment, in com-
bination with MTX, for a mean duration of 5.3 ± 2.0 years.
The characteristics of the MTX- and biologic-treated RA
subsets are shown in Table 1.
For this study, a cohort of 60 age-matched women
without RA who were undergoing TCD investigations
were chosen as the control group. These individuals
were part of a TCD screening program conducted in the
Miskolc region. The mean age of these 60 individuals
was 58.4 ± 4.4 years. The age of control subjects was not
significantly different from that of patients with RA.
Ethical approval (1046-63/2015) was obtained from the
University of Miskolc Regional/Institutional Review Board.
All patients signed informed consent forms. The study
was performed according to the Declaration of Helsinki.
Determination of temporal acoustic windows
Before the TCD assessment was carried out by US, an
ultrasonographer (MS) determined whether the right
and left TAWs were detectable and available for TCD
measurements. Only patients and control subjects with
detectable TAWs could be further analysed by TCD.
Transcranial Doppler assessment
The Doppler effect means that if US waves strike a mov-
ing object, such as an erythrocyte, the reflected wave
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undergoes a change in frequency (Doppler shift) which
is directly proportional to the velocity of the reflector. A
US frequency of < 2 MHz is required to penetrate the
skull and reach the intracranial vasculature. Acoustic
windows are either foramina or thin bone that allow US
waves to reach the cerebral circulation. The TAW lo-
cated above the zygomatic ridge is most frequently used
for detection of the anterior cerebral artery, MCA or
posterior cerebral artery, as well as the terminal internal
carotid artery (ICA) [6]. Unfortunately, as described
above, approximately 8–20% of individuals [10] may
have TAW failure.
In this study, MCAs were assessed by TCD using a
Multi-Dop T Digital (DWL Compumedics GmbH,
Singen, Germany) device. Among TCD indices, MFV
(cm/second), peak systolic flow velocity (PSFV) and end
diastolic flow velocity (EDFV) are key parameters in
TCD assessment. MFV is the mean velocity within a
cardiac cycle. Increased MFV may indicate stenosis,
vasospasm or hyperdynamic flow. A decreased value
may indicate hypotension, decreased cerebral blood flow
and intracranial pressure.
The PI, calculated as (PSFV − EDFV)/MFV, provides in-
formation on downstream cerebral vascular resistance
(normal range 0.6–1.2). Proximal stenosis or occlusion
may lower the PI below 0.5, whereas distal occlusion or
constriction may increase the PI above 1.2. The resistivity
(resistance) index (RI), calculated as (PSFV − EDFV)/
PSFV (normal range 0.4–0.7), indicates downstream
resistance.
Cerebrovascular reserve capacity (CRC) is the physio-
logical vasoconstrictive and vasodilatory function of pre-
capillary (resistance) arteries that maintains optimal
cerebral blood flow even if cerebral perfusion pressure
changes. In the MCAs, CRC in percent is calculated as
(PSFV −MFV)/MFV × 100. A normal response in MFV
values after acetazolamide is a 29 cm/second increase in
women and 21 cm/second increase in men [11], which
corresponds to 49.3% and 38.9% CRC, respectively.
First, MFV, PI and RI were determined at rest (r)
[MFV(r), PI(r), RI(r)]. Then, provocation manoeuvres
were performed, including hyperventilation (h) for
30 seconds [MFV(h), PI(h), RI(h)], followed by, after
normal breathing, apnoea (a) for 30 seconds [MFV(a),
PI(a), RI(a)] [12]. After these manoeuvres, the flow
velocity in MCA should increase by at least 15% under
normal conditions; otherwise, severely impaired CRC is
present [12].
The TCD procedure was performed by a single
technician (MS) and validated by a neurosurgeon/
Table 1 General characteristics and laboratory markers of assessed patients with rheumatoid arthritis and control subjects
RA total RA MTX RA biologic Control subjects
No. of subjects 41 12 29 60
Age, years 58.24 ± 9.72 58.67 ± 9.88 58.07 ± 9.88 58.42 ± 4.41
Disease duration. years 12.15 ± 8.03 11.00 ± 8.63 12.62 ± 7.87 –
RF positivity, % 70% 82% 66% –
Anti-CCP positivity, % 65% 75% 64% –
MTX duration, years 6.15 ± 5.82 5.83 ± 4.57 6.28 ± 3.54 –
MTX dose, mg/week 14.63 ± 6.11 14.17 ± 5.15 14.83 ± 6.54 –
Biologic duration, years 5.31 ± 2.04 – 5.31 ± 2.04 –
DAS28 2.44 ± 0.87 2.88 ± 0.75 2.26 ± 0.86 –
ESR, mm/h 17.07 ± 15.09 17.00 ± 9.16 17.10 ± 17.10 5.30 ± 2.40
hsCRP, mg/L 3.93 ± 4.53 5.31 ± 3.90 3.36 ± 4.70 0.30 ± 0.30
BMI, kg/m2 28.38 ± 5.51 28.08 ± 6.77 28.51 ± 5.02 30.20 ± 8.70
TC, mmol/L 5.34 ± 1.08 5.63 ± 1.00 5.23 ± 1.10 5.27 ± 1.15
HDL-C, mmol/L 1.47 ± 0.43 1.38 ± 0.53 1.49 ± 0.40 1.70 ± 0.42
TC/HDL-C ratio 3.94 ± 1.36 4.70 ± 3.73 3.73 ± 1.20 3.62 ± 0.95
LDL-C, mmol/L 3.17 ± 0.82 3.36 ± 0.90 3.12 ± 0.81 3.40 ± 0.94
TG, mmol/L 1.46 ± 0.68 1.53 ± 0.76 1.43 ± 0.66 1.49 ± 0.61
Lp(a), ng/L 260.14 ± 317.20 345.29 ± 426.55 239.59 ± 290.74 –
ApoA/ApoB ratio 1.81 ± 0.51 1.71 ± 0.49 1.83 ± 0.53 –
Abbreviations: Apo Apolipoprotein, BMI Body mass index, CCP Cyclic citrullinated peptide, CRC Cerebrovascular reserve capacity, DAS28 28-joint Disease Activity
Score, ESR Erythrocyte sedimentation rate, HDL-C High-density lipoprotein cholesterol, hsCRP High-sensitivity C-reactive protein, LDL-C Low-density lipoprotein
cholesterol, Lp(a) Serum lipoprotein A, MTX Methotrexate, RA Rheumatoid arthritis, RF Rheumatoid factor, TC Total cholesterol, TG Triglyceride
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neuroradiologist (CO). All the above-mentioned parame-
ters were determined in the RA cohort. In control subjects,
all parameters described above could also be assessed.
Carotid artery ultrasound examination
Carotid artery assessments were carried out in all pa-
tients with RA (n = 41) and control subjects (n = 60)
using a duplex US system (Vivid e; GE Healthcare,
Wauwatosa, WI, USA) using a 5-MHz linear array trans-
ducer (GE 8 L-RS probe; GE Healthcare) as described by
us elsewhere [13]. Assessments were performed by a sin-
gle observer (AS). In brief, five measurements were per-
formed on the posterior wall of the distal part of
common carotid artery (CCA), proximal to the carotid
bulb. Longitudinal high-resolution B-mode US scans
were employed over both the right and left CCAs and
were R-synchronised and recorded. Carotid intima-
media thickness (cIMT) was defined as the distance be-
tween the first and second echogenic lines from the
lumen, taking the average of five measurements on both
sides. cIMT values were expressed in millimetres.
During US assessments, all visible plaques were de-
tected and counted, and their characteristics (fibrous,
calcified or soft, presence or absence of stenosis) were
determined. Soft plaques representing unstable plaques
are more dangerous than fibrous or calcified ones [13, 14].
A ‘plaque score’ of 0–5 was also assigned to each patient,
with scores of 0–5 representing no plaque, fibrous,
non-stenotic calcified, stenotic calcified, soft and sten-
otic soft, respectively.
Brain MRI investigations
All 41 patients with RA also underwent brain MRI stud-
ies to be assessed for focal vascular lesions, emollition
and atrophy. For this purpose, a MAGNETOM Verio
3 T MRI instrument (Siemens, Munich, Germany) was
used. All MRI scans were obtained by a single radiologist
(LK) and read by a neurosurgeon/neuroradiologist (CO).
The presence or absence of vascular lesions, emollition
and/or atrophy was noted.
Laboratory assessments
Serum IgM RF and high-sensitivity C-reactive protein
(hsCRP) were assessed by quantitative nephelometry
(COBAS MIRA Plus; Roche Diagnostics, Indianapolis, IN,
USA), using RF and CRP reagents, respectively (both from
DIALAB, Wiener Neudorf, Austria). RF levels > 50 IU/ml
indicated seropositivity, and hsCRP levels > 5 mg/L were
considered elevated. Anti-CCP autoantibodies were de-
tected in serum samples using the second-generation
Immunoscan-RA CCP2 enzyme-linked immunosorbent
assay (Euro-Diagnostica, Arnhem, The Netherlands).
The assay was performed according to the instructions
of the manufacturer. A concentration > 25 IU/ml indi-
cated seropositivity.
After overnight fasting, blood samples were taken
from the patients and control subjects for total choles-
terol (TC), low-density lipoprotein cholesterol (LDL-C),
high-density lipoprotein cholesterol (HDL-C) and tri-
glycerides. Lipids were determined using routine labora-
tory methods. Serum lipoprotein A [Lp(a)] was assessed by
latex-sensitised immunoturbidimetry (Roche Diagnostics).
Serum apolipoprotein A (ApoA) and ApoB levels were
measured by immunoturbidimetry using Tina-quant
Apoliporotein A and Apoliporotein B reagents (Roche
Diagnostics) and a cobas Integra 700 analyser (Roche
Diagnostics). ApoB/ApoA ratio, a good marker for athero-
sclerotic risk [15, 16], was calculated (Table 1).
Statistical analysis
The statistical analysis was performed with IBM SPSS
Statistics version 22 software (IBM, Armonk, NY, USA).
The data are expressed as mean ± SD and as frequency
and percentage. Continuous variables were evaluated by
paired two-tailed t tests and Wilcoxon’s test. Nominal
variables were compared between groups using the chi-
square or Fisher’s exact test, as appropriate. Simple cor-
relations were determined by Spearman’s correlation
analysis. Multiple linear regression using the stepwise
method was used to determine correlations and inde-
pendent associations between parameters. TCD/carotid
parameters were the dependent variables, and other
clinical and laboratory parameters (e.g., age, disease
duration, RF and anti-CCP positivity, MTX dose and
duration, biologic therapy duration, 28-joint Disease
Activity Score [DAS28], erythrocyte sedimentation rate,
hsCRP, body mass index [BMI], lipids) were independent
variables. The β standardised linear coefficients showing
linear correlations between two parameters were
determined. The B regression coefficient (with 95% CI) in-
dicated an independent association between the dependent
and independent variables during changes. p values < 0.05
were considered significant.
Results
Comparative description of RA subsets
With respect to clinical and laboratory characteristics
(Table 1), the total RA cohort, MTX- and biologic-treated
patients did not differ from each other in most respects.
However, MTX-treated patients had significantly higher
CRP (5.3 ± 3.9 mg/L vs 3.4 ± 4.7 mg/L; p < 0.05) and mean
DAS28 (2.88 ± 0.75 vs 2.26 ± 0.86; p = 0.006) than any
biologic-treated ones (Table 1). Numerous lipid parame-
ters have been studied. Results showing no major differ-
ences between RA subsets are provided in Table 1.
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TCD assessments in patients with RA, RA subsets and
control subjects
Right and left MCA PI, RI and MFV values at rest (r)
and after hyperventilation (h) and apnoea (a); right and
left CRC values; and basilar artery PI(r) and MFV(r)
values of patients with RA and control subjects have
been evaluated and are presented. MCA PI and RI values
detected at rest (r), after apnoea (a) and hyperventilation
(h) are shown in Figs. 1 and 2. With respect to right and
left MCA PI(r), all patients with RA (right 0.90 ± 0.18,
p < 0.001; left 0.89 ± 0.19, p = 0.003) and MTX-treated pa-
tients (right 0.97 ± 0.12, p < 0.001; left 1.00 ± 0.19, p < 0.001)
had significantly higher PI(r) values than control subjects
(right 0.78 ± 0.13; left 0.77 ± 0.44) (Fig. 1a). Biologic-treated
patients with RA exerted significantly higher left MCA
PI(r) than control subjects (0.83 ± 0.17 vs 0.77 ± 0.44,
p = 0.021) but significantly lower left MCA PI(r) than
MTX-treated patients (0.83 ± 0.17 vs 1.00 ± 0.19, p = 0.021)
(Fig. 1a).
With regard to right and left MCA PI(a), the total RA co-
hort (right 0.83 ± 0.16, p < 0.001; left 0.85 ± 0.03, p = 0.002)
and MTX-treated patients (right 0.90 ± 0.15, p < 0.001; left
0.90 ± 0.15, p = 0.009) had significantly higher PI(a) values
than control subjects (right 0.69 ± 0.17; left 0.68 ± 0.25)
(Fig. 1b). On one hand, the total and MTX-treated RA
population did not differ from control subjects in PI(h)
values. On the other hand, biologic-treated patients with
RA exerted significantly lower left MCA PI(h) than MTX-
treated patients (0.99 ± 0.25 vs 1.23 ± 0.29, p = 0.029)
(Fig. 1c).
Right and left MCA RI(r) values were also signifi-
cantly higher in the total (right 0.58 ± 0.07, p < 0.001;
left 0.58 ± 0.08, p = 0.004) and MTX-treated patients
with RA (right 0.61 ± 0.06, p < 0.001; left 0.62 ± 0.07,
p < 0.001) than control subjects (right 0.53 ± 0.08; left
0.53 ± 0.07) (Fig. 2a). Biologic-treated patients with RA
had significantly higher left MCA RI(r) than control sub-
jects (0.55 ± 0.07 vs 0.53 ± 0.07, p = 0.018) but significantly
lower left MCA RI(r) than MTX-treated patients (0.55 ±
0.07 vs 0.62 ± 0.07, p = 0.018) (Fig. 2a).
Right and left RI(a) was also significantly higher in all pa-
tients with RA (right 0.56 ± 0.07, p < 0.001; left 0.56 ± 0.02,
p < 0.001) and in MTX-treated patients with RA (right
0.58 ± 0.06, p < 0.001; left 0.59 ± 0.07, p < 0.001) than in
control subjects (right 0.49 ± 0.08; left 0.49 ± 0.07) (Fig. 2b).
Finally, patients with RA did not differ from control sub-
jects in right MCA RI(h) values. However, MTX-treated
patients with RA exerted significantly higher left MCA
RI(h) than control subjects (0.69 ± 0.07 vs 0.62 ± 0.29,
p = 0.09) (Fig. 2c). Basilar artery PI(r) was also increased
in the total RA cohort (0.98 ± 0.26, p = 0.005) and in
MTX-treated patients (1.05 ± 0.38, p = 0.001) compared
with control subjects (0.85 ± 0.15) (Fig. 3).
The right and left CRC was significantly impaired in
all patients with RA (right 27.5 ± 12.5%, p < 0.001; left
27.3 ± 13.5, p < 0.001), MTX-treated patients with RA
(right 24.5 ± 9.8, p = 0.005; left 25.6 ± 7.6, p = 0.002) and
biologic-treated patients with RA (right 28.8 ± 13.5,
p < 0.001; left 28.2 ± 15.9, p < 0.001) compared with con-
trol subjects (right 50.2 ± 30.6; left 44.0 ± 17.6) (Fig. 4).
Fig. 1 MCA PI(r) (a), PI(a) (b) and PI(h) (c) values in patients with RA and control subjects. See text for abbreviations. a *p < 0.001 vs controls;
#p < 0.05 vs controls; @p < 0.001 vs MTX. b *p < 0.001 vs controls; #p < 0.05 vs controls. c @p < 0.05 vs MTX
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Finally, in addition to the significant differences de-
scribed above, right MCA PI(r), PI(a), PI(h), RI(r),
RI(a), RI(h), left MCA PI(a), RI(a), RI(h), basilar artery
PI(r) values exerted a tendency of being increased in
MTX-treated vs biologic-treated patients (Figs. 1, 2
and 3). Also, right and left MCA CRC was non-
significantly lower in MTX-treated than in biologic-treated
patients (Fig. 4).
Carotid artery assessments
The right and left carotid arteries could be assessed in all
patients with RA (n = 41) and control subjects (n = 60).
With respect to the right carotid, the percentage of pa-
tients with at least one plaque was significantly higher in
all patients with RA (51%; p = 0.021) and MTX-treated
subjects (67%; p = 0.016) than in control subjects (27%).
There was no difference between the subsets with regard
to left carotid plaque percentages (Table 2). Likewise, the
right but not the left carotid plaque score as defined above
was also significantly higher in the total (1.22 ± 1.35;
p = 0.016) and MTX-treated RA subset (1.58 ± 1.31;
p = 0.08) (Table 2).
The cIMT of the right carotid artery was 0.72 ± 0.24 mm
in the total RA cohort and 0.40 ± 0.28 mm in control sub-
jects (p < 0.001). Similarly, the left carotid cIMT was
greater in RA (0.73 ± 0.23 mm) than in control subjects
(0.40 ± 0.28 mm) (p < 0.001). Right and left cIMT were also
significantly higher in MTX-treated (right 0.72 ± 0.25 mm,
p < 0.001; left 0.69 ± 0.22 mm, p < 0.001) and biologic-
treated patients (right 0.72 ± 0.23, p < 0.001; left 0.75 ±
0.24 mm0, p < 0.001) than in control subjects (right 0.40 ±
0.28 mm; left 0.40 ± 0.28 mm) (Table 2).
Fig. 2 MCA RI(r) (a), RI(a) (b) and RI(h) (c) values in patients with RA and control subjects. See text for abbreviations. a *p < 0.001 vs controls;
#p < 0.05 vs controls; @p < 0.05 vs MTX b *p < 0.001 vs controls c #p < 0.05 vs controls
Fig. 3 Basilar artery PI(r) values in patients with RA and control
subjects. See text for abbreviations. #p < 0.05 vs controls
Fig. 4 MCA CRC values in patients with RA and control subjects.
See text for abbreviations. *p < 0.001 vs controls; #p < 0.05 vs controls
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Brain MRI investigations
As described above, 3-T brain MRI investigations were
carried out in the 41 patients with RA. Altogether, 39%
of all patients with RA, 42% of MTX- and 38% of
biologic-treated patients with RA had at least one vascu-
lar lesion in the right and left cerebral hemispheres.
Only two patients had signs of emollition, whereas eight
patients had cerebral atrophy. There were no statistical
differences between MTX- and biologic-treated patients
(Table 2).
Associations of TCD, carotid features and other
parameters in patients with RA
As described above, multiple linear regression analysis
was performed to determine associations between TCD/
carotid parameters as dependent variables and other
independent clinical and laboratory variables. As shown
in Table 3, numerous TCD variables correlated with age.
When assessing disease-related factors, left MCA PI(r)
and PI(h) correlated positively, whereas right MCA CRC
inversely correlated, with disease activity. With respect to
metabolic factors, right PI(h) and right cIMT correlated
with BMI. Left RI(h) inversely correlated with HDL-C.
We also correlated TCD variables with carotid US and
brain MRI results. When comparing patients with RA
with (n = 18) and without (n = 23) left carotid plaques,
we found that right MCA PI(a), RI(r) and RI(a), as well
as left MCA PI(a), PI(h) and RI(a), values were signifi-
cantly higher in patients with carotid plaques (Table 4).
In addition, right MCA PI(h) significantly correlated
with right cIMT (R = 0.377, p = 0.018) (data not shown).
TCD and carotid parameters did not show significant as-
sociations with any brain MRI findings (data not shown).
Discussion
RA has been associated with accelerated atherosclerosis
leading to increased cardiovascular and cerebrovascular
morbidity and mortality [2–5, 17, 18]. Cerebrovascular
disease and stroke may occur with uncontrolled, more
severe disease [5, 17–19]. It is very important to assess
Table 2 Carotid intima-media thickness and brain magnetic resonance imaging assessments
RA total
(n = 41)
RA MTX
(n = 12)
RA biologic
(n = 29)
Control subjects
(n = 60)
p Value
RA total vs
control subjects
RA MTX vs
control subjects
RA biologic vs
control subjects
RA MTX vs
RA biologic
Carotid ultrasound studies
Right cIMT (mm) 0.72 ± 0.24 0.72 ± 0.25 0.72 ± 0.23 0.40 ± 0.28 <0.001 <0.001 <0.001
Left cIMT (mm) 0.73 ± 0.23 0.69 ± 0.22 0.75 ± 0.24 0.40 ± 0.28 <0.001 <0.001 <0.001
Right carotid plaques (%) 21 (51%) 8 (67%) 13 (45%) 16 (27%) 0.021 0.016
Left carotid plaques (%) 18 (44%) 6 (50%) 12 (41%) 21 (35%)
Right carotid plaque
score
1.22 ± 1.35 1.58 ± 1.31 1.07 ± 1.36 0.60 ± 0.99 0.016 0.008
Left carotid plaque
score
1.00 ± 1.16 1.25 ± 1.55 0.90 ± 0.98 0.78 ± 1.12
Brain MRI studies
Right vascular lesions (%) 16 (39%) 5 (42%) 11 (38%)
Left vascular lesions (%) 16 (39%) 5 (42%) 11 (38%)
Emollition 2 (5%) 0 2 (7%)
Atrophy 8 (20%) 1 (8%) 7 (24%)
Abbreviations: cIMT Carotid intima-media thickness, MRI Magnetic resonance imaging, MTX Methotrexate, RA Rheumatoid arthritis
Table 3 Associations between transcranial Doppler/carotid
parameters and other variablesa
Parameter 1 Parameter 2 B (95% CI) β p Value
Right PI(r) Age 0.007 (0.002–0.013) 0.384 0.011
Right RI(r) Age 0.004 (0.002–0.006) 0.508 0.001
Right PI(h) BMI 0.024 (0.006–0.042) 0.410 0.011
Right RI(h) Age 0.004 (0.002–0.007) 0.456 0.002
Left PI(r) Age 0.009 (0.002–0.017) 0.447 0.012
Left RI(r) Age 0.004 (0.001–0.007) 0.459 0.011
Left PI(a) DAS28 0.086 (0.013–0.159) 0.368 0.023
Left PI(h) CRP 0.028 (0.005–0.050) 0.442 0.016
DAS28 0.087 (0.008–0.166) 0.372 0.032
Left RI(h) HDL-C −0.104 (−0.203–0.006) −0.415 0.039
Basilar PI Age 0.008 (0.002–0.014) 0.325 0.010
Right CRC DAS28 −4.633 (−9.047–0.219) −0.326 0.040
Right cIMT BMI 0.002 (0–00.3) 0.306 0.015
Abbreviations: β Standardised linear coefficient, B (+95% CI) Regression
coefficient, BMI Body mass index, CRP C-reactive protein, CRC Cerebrovascular
reserve capacity, DAS28 28-joint Disease Activity Score, HDL-C High-density
lipoprotein cholesterol, PI Pulsatility index, RI Resistivity (resistance) index
aMultiple linear regression
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the intracranial vessels as well as the carotid arteries in
order to determine cerebrovascular risk and the preclin-
ical status of patients [14, 19, 20]. To our knowledge, to
date, no systematic evaluation of intracranial circulation
using functional TCD has been performed. In addition,
we believe this is the first study including use of TCD,
assessment of carotid arteries and brain MRI in the very
same RA cohort. Because of the lack of literature data,
we could not compare our findings with data reported
by others.
TCD allows dynamic monitoring of cerebral circula-
tion [6]. TCD is a very convenient, cheap and portable
technique that can be used at the bedside. TCD may be
able to assess the pathophysiology and outcome of cere-
bral ischemia [7]. Moreover, MCA may be the most rele-
vant vessel to study by TCD. MCA stenosis, as well as
MCA PI, MFV and PI/MFV ratio, has been associated
with stroke, and all are important predictors of future
cerebrovascular events [8, 9].
TAW failure may limit the performance of TCD. Ap-
proximately 8–20% of people in the general population
have undetectable TAW [10]. There has been no report
on TAW failure in patients with RA. Very recently, we
have found that TAW failure was significantly more
common in RA than among the general population
(Kardos et al., submitted). Therefore, before performing
TCD measurements, we looked for right and left TAWs.
Eventually, 41 consecutive patients were suitable for
TCD, carotid artery and brain MRI studies.
We performed a detailed TCD assessment in a homo-
geneous RA population and with age-matched, healthy
control subjects. We also compared patients treated with
MTX and biologics including IFX and TCZ. The total,
MTX-treated and biologic-treated patients did not differ
from each other in most respects. MTX-treated patients
had higher disease activity than biologic-treated patients.
With respect to MCA, PI and RI at rest and after ap-
noea measured on both sides were significantly higher in
RA, indicating increased distal occlusion and resistance,
respectively. Patients with RA also had an impaired
CRC, as indicated by lower CRC. Significantly higher PI
was detected in the basilar artery as well. With regard to
treatment, MTX-treated patients had higher PI and RI
values than biologic-treated patients. For example, left
MCA PI(r), PI(h) and RI(r) were significantly lower in
biologic-treated patients than in MTX-treated patients.
Furthermore, right MCA PI(r) and RI(r), as well as right
and left MCA PI(a) and RI(a), were still increased in
MTX-treated patients compared with control subjects,
whereas these parameters were similar to those of
biologic-treated patients. These data suggest that pa-
tients with RA have impaired circulation in the MCA
and basilar arteries compared with control subjects.
Furthermore, biologics may improve numerous MCA
parameters to a greater extent than MTX.
The carotid arteries were also assessed for signs of ath-
erosclerosis. More patients with RA than control sub-
jects had at least one plaque in the right carotid artery,
and right carotid plaque score was also higher in
patients with RA. There were no differences among RA
subsets regarding the presence of plaques or plaque
scores. The cIMT of the right and left carotid arteries
was also much higher in the total, MTX-treated and
biologic-treated patients with RA than in control sub-
jects. We and others have previously reported increased
cIMT and plaques in RA [13, 20–25]. In this cohort, the
differences in cIMT between patients with RA and con-
trol subjects are really large, probably due to the fact
that mostly patients with severe RA who needed bio-
logics were selected. Carotid arteries have not yet been
studied in conjunction with TCD in patients with RA.
Brain MRI investigations were carried out to deter-
mine cerebral vascular lesions. About half of patients
with RA developed vascular lesions in the right or left
hemisphere. Somewhat greater proportions of MTX-
treated than biologic-treated patients who developed
vascular lesions. We also detected signs of cerebral
emollition and atrophy in about 5% and 24%, res-
pectively, of patients with RA. We have not found any
reports with respect to cerebral emollition in RA.
Wartolowska et al. [26] also detected some atrophy in
patients with RA. Bekkelund et al. [27] performed a
quantitative cerebral MRI study in 1995. They did not
find any differences in the prevalence of atrophy in pa-
tients with RA and control subjects [27].
Multiple linear regression analysis suggested the associa-
tions of multiple TCD parameters with age. Some parame-
ters also correlated with RA disease activity. When TCD
and carotid assessment results were correlated, numerous
TCD variables were increased in patients with left carotid
plaques. Right PI(h) also correlated with right cIMT. These
correlations should be confirmed in larger future studies.
However, comparative TCD, carotid US and brain MRI
studies have not yet been performed in patients with RA.
Table 4 Associations between transcranial Doppler and left
carotid artery plaques
TCD variable Presence of
plaque (n = 18)
Absence of
plaque (n = 23)
p Value
Right PI(a) 0.92 ± 0.17 0.77 ± 0.12 0.002
Right RI(r) 0.61 ± 0.07 0.56 ± 0.07 0.021
Right RI(a) 0.59 ± 0.09 0.53 ± 0.05 0.007
Left PI(a) 0.94 ± 0.18 0.79 ± 0.17 0.032
Left PI(h) 1.23 ± 0.29 0.94 ± 0.25 0.021
Left RI(a) 0.61 ± 0.10 0.53 ± 0.07 0.022
Abbreviations: PI Pulsatility index, RI Resistivity (resistance) index,
TCD Transcranial Doppler
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Conclusions
To our knowledge, this is the first detailed study using
TCD to assess intracranial arteries in RA compared with
control subjects. We also included carotid assessment
and brain MRI in the same patients. We found more pro-
nounced distal occlusion and resistance of the MCA along
with impaired CRC in patients with RA compared with
control subjects. We confirmed that carotid plaques and
increased cIMT occur in patients with RA, and we de-
scribed cerebral vascular lesions, emollition and atrophy
in a group of patients with RA. With respect to therapy,
biologic treatment, in comparison with MTX, may have
more pronounced effects on some TCD PI and RI indices.
Preclinical cerebrovascular screening may be important in
determining stroke risk in individuals with RA.
Key messages
 Increased distal MCA and basilar artery occlusion was
detected in patients with RA, as determined by TCD.
 Patients with RA also have CRC defects.
 Biologics may beneficially influence some
parameters in the intracranial vessels.
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